The National Allied Procurement Office has released a notification regarding Round 9 of the national Volume-Based Procurement (VBP) tender program. This year introduces a novelty where all drugs with marketing approvals before October 30, 2023, are eligible to apply for inclusion in the VBP tender before November 2, provided their molecule names are listed in the previously released scope of the VBP tender.
Eligibility and Inclusion Criteria
Notably, the invitation extends to all same-name drugs that have passed the generic quality consistency evaluation (GQCE) process, regardless of the specific specifications originally targeted in Round 9. This inclusive approach aims to broaden the range of drugs available for procurement.
Tender Details and Rule Refinements
The highest valid quotation for each specification will be calculated based on existing price ratios, with the initial agreed procurement volume set at “0”. The 9th VBP tender is scheduled to take place in Shanghai on November 6 and includes several rule refinements. These refinements set the deadline of October 30 for drugs to gain GQCE approval and voluntarily seek inclusion. Additional measures ensure that drug consortiums cannot win multiple bids for the same product and extend the procurement cycle to 4 years.-Fineline Info & Tech
